药品注册申请号:018927
申请类型:NDA (新药申请)
申请人:NOVARTIS
申请人全名:NOVARTIS PHARMACEUTICALS CORP
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 TEGRETOL CARBAMAZEPINE SUSPENSION;ORAL 100MG/5ML Yes Yes AB 1987/12/18 1987/12/18 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2023/09/13 SUPPL-60(补充) Approval Labeling STANDARD
2018/03/20 SUPPL-55(补充) Approval Labeling STANDARD
2016/07/08 SUPPL-52(补充) Approval Manufacturing (CMC) STANDARD
2016/06/17 SUPPL-51(补充) Approval Manufacturing (CMC) STANDARD
2015/08/28 SUPPL-38(补充) Approval Labeling STANDARD
2014/09/16 SUPPL-40(补充) Approval Labeling STANDARD
2014/01/16 SUPPL-44(补充) Approval Labeling UNKNOWN
2013/11/08 SUPPL-49(补充) Approval Manufacturing (CMC) STANDARD
2013/03/06 SUPPL-46(补充) Approval Labeling STANDARD
2012/12/11 SUPPL-48(补充) Approval Labeling STANDARD
2011/10/30 SUPPL-47(补充) Approval REMS N/A
2011/03/03 SUPPL-42(补充) Approval Labeling STANDARD
2011/03/03 SUPPL-41(补充) Approval Labeling STANDARD
2009/04/23 SUPPL-43(补充) Approval Labeling 901 REQUIRED
2007/12/11 SUPPL-39(补充) Approval Labeling STANDARD
2007/08/16 SUPPL-35(补充) Approval Labeling STANDARD
2002/12/11 SUPPL-34(补充) Approval Manufacturing (CMC) STANDARD
2002/01/28 SUPPL-33(补充) Approval Manufacturing (CMC) STANDARD
2001/11/15 SUPPL-32(补充) Approval Manufacturing (CMC) STANDARD
2001/03/07 SUPPL-31(补充) Approval Labeling STANDARD
2000/04/11 SUPPL-30(补充) Approval Manufacturing (CMC) STANDARD
2000/04/10 SUPPL-28(补充) Approval Labeling STANDARD
2000/04/10 SUPPL-24(补充) Approval Labeling STANDARD
2000/03/08 SUPPL-29(补充) Approval Manufacturing (CMC) STANDARD
1999/02/19 SUPPL-26(补充) Approval Manufacturing (CMC) STANDARD
1998/12/29 SUPPL-27(补充) Approval Manufacturing (CMC) STANDARD
1998/07/15 SUPPL-25(补充) Approval Labeling STANDARD
1998/07/15 SUPPL-23(补充) Approval Labeling STANDARD
1998/07/15 SUPPL-21(补充) Approval Labeling STANDARD
1998/07/15 SUPPL-20(补充) Approval Labeling STANDARD
1997/01/02 SUPPL-22(补充) Approval Manufacturing (CMC) STANDARD
1995/10/11 SUPPL-18(补充) Approval Efficacy STANDARD
1995/08/09 SUPPL-19(补充) Approval Manufacturing (CMC) STANDARD
1993/10/06 SUPPL-16(补充) Approval Manufacturing (CMC) STANDARD
1991/03/14 SUPPL-10(补充) Approval Manufacturing (CMC) STANDARD
1990/03/26 SUPPL-8(补充) Approval Labeling
1989/08/01 SUPPL-6(补充) Approval Manufacturing (CMC) STANDARD
1989/07/21 SUPPL-5(补充) Approval Labeling
1989/04/07 SUPPL-4(补充) Approval Manufacturing (CMC) STANDARD
1988/08/01 SUPPL-3(补充) Approval Labeling
1988/07/28 SUPPL-2(补充) Approval Manufacturing (CMC) STANDARD
1988/07/28 SUPPL-1(补充) Approval Manufacturing (CMC) STANDARD
1987/12/18 ORIG-1(原始申请) Approval Type 3 - New Dosage Form STANDARD
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:CARBAMAZEPINE 剂型/给药途径:SUSPENSION;ORAL 规格:100MG/5ML 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
018927 001 NDA TEGRETOL CARBAMAZEPINE SUSPENSION;ORAL 100MG/5ML Prescription Yes Yes AB 1987/12/18 NOVARTIS
075714 001 ANDA CARBAMAZEPINE CARBAMAZEPINE SUSPENSION;ORAL 100MG/5ML Prescription No No AB 2002/06/05 CHARTWELL RX
076729 001 ANDA TERIL CARBAMAZEPINE SUSPENSION;ORAL 100MG/5ML Prescription No No AB 2004/09/20 TARO
214277 001 ANDA CARBAMAZEPINE CARBAMAZEPINE SUSPENSION;ORAL 100MG/5ML Prescription No No AB 2022/10/06 NOVITIUM PHARMA
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database